<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00220155</url>
  </required_header>
  <id_info>
    <org_study_id>2398</org_study_id>
    <nct_id>NCT00220155</nct_id>
  </id_info>
  <brief_title>Phase II Fixed Dose Rate Gemcitabine for Advanced or Metastatic Colorectal Cancer</brief_title>
  <official_title>A Phase II Trial of Fixed Dose Rate Gemcitabine in Patients With Advanced or Metastatic Colorectal Cancer.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Royal Marsden NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Royal Marsden NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the efficacy and safety of gemcitabine given by fixed dose rate intravenous&#xD;
      infusion in patients with pretreated metastatic colorectal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Previous lines of treatment recorded. Adjuvant and palliative.&#xD;
&#xD;
      Treatment will continue until clinical indication due to PD or toxicity, or until completion&#xD;
      of 6 cycles of gemcitabine, whichever comes first.&#xD;
&#xD;
      All patients will be assessed for toxicity and followed up for disease&#xD;
      recurrence/progression.&#xD;
&#xD;
      The study will be divided into two accrual stages - the first consisting of 17 patients. If 6&#xD;
      or more patients achieve tumour response or stabilisation in the first stage, the second&#xD;
      stage will commence accrual of a further 20 patients. Hence, the total planned accrual will&#xD;
      be 37 patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2004</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients obtaining disease control in the form of tumour response or stabilisation</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment related toxicity</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
  </secondary_outcome>
  <enrollment type="Actual">16</enrollment>
  <condition>Colorectal Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt;18 years&#xD;
&#xD;
          -  Histologically proven colorectal adenocarcinoma.&#xD;
&#xD;
          -  Locally advanced (inoperable) or metastatic colorectal carcinoma treated with at least&#xD;
             one prior chemotherapy regimen.&#xD;
&#xD;
          -  Progressive disease documented by CT either during or within 3 months of completion of&#xD;
             previous chemotherapy&#xD;
&#xD;
          -  No previous malignant disease other than non-melanotic skin cancer or&#xD;
             carcinoma-in-situ of the uterine cervix.&#xD;
&#xD;
          -  Unidimensional measurable disease as assessed by CT.&#xD;
&#xD;
          -  Adequate bone marrow function; Hb &gt;10g/dl, platelets &gt;100 x109/l, WBC &gt;3x109/l, Neut&#xD;
             &gt;1.5x109/l.&#xD;
&#xD;
          -  Adequate liver function: Serum Bilirubin &lt;1.5 x upper limit of normal&#xD;
&#xD;
          -  Adequate renal function: Serum Creatinine &lt; 0.11 mmol/L&#xD;
&#xD;
          -  No concurrent uncontrolled medical conditions&#xD;
&#xD;
          -  WHO performance status 0,1 or 2&#xD;
&#xD;
          -  Adequate contraceptive precautions, if appropriate&#xD;
&#xD;
          -  Informed written consent&#xD;
&#xD;
          -  Negative pregnancy test in women of child bearing age&#xD;
&#xD;
          -  Life expectancy &gt; 3 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Medical or psychiatric condition that comprise the patient's ability to take informed&#xD;
             consent.&#xD;
&#xD;
          -  Patients within 4 weeks of chemotherapy or radiotherapy (6 weeks for nitrosureas or&#xD;
             mitomycin C).&#xD;
&#xD;
          -  Previous treatment with gemcitabine.&#xD;
&#xD;
          -  Patients with uncontrolled cerebral metastases.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Cunningham</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Marsden NHS Foundation Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royal Marsden Hospital</name>
      <address>
        <city>Sutton</city>
        <state>Surrey</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2009</verification_date>
  <study_first_submitted>September 20, 2005</study_first_submitted>
  <study_first_submitted_qc>September 20, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <last_update_submitted>December 15, 2009</last_update_submitted>
  <last_update_submitted_qc>December 15, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2009</last_update_posted>
  <responsible_party>
    <name_title>Jane Lawrence</name_title>
    <organization>Royal Marsden NHS Foundation Trust</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

